Clinical Trial Update: Gemcitabine With or Without Tipifarnib (R115777) in Treating Patients With Advanced Pancreatic Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating gemcitabine with or without tipifarnib in advanced pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemzar) (gemcitabine)
• Tipifarnib (tipifarnib)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Pancreatic Neoplasms | Phase 3 | Status: COMPLETED